VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 94 filers reported holding VERONA PHARMA PLC in Q1 2023. The put-call ratio across all filers is 1.24 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,812,308 | -19.6% | 417,933 | +4.2% | 1.25% | -15.0% |
| Q2 2023 | $8,476,865 | -13.5% | 400,987 | -17.8% | 1.47% | -31.1% |
| Q1 2023 | $9,798,940 | -9.5% | 487,995 | +17.7% | 2.13% | -26.1% |
| Q4 2022 | $10,829,526 | +227.8% | 414,448 | +28.2% | 2.88% | +207.1% |
| Q3 2022 | $3,304,000 | – | 323,273 | – | 0.94% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,332,485 | $34,817,833 | 22.99% |
| Abingworth LLP | 2,457,500 | $64,214,475 | 20.92% |
| Fairmount Funds Management LLC | 2,875,526 | $75,137,494 | 11.92% |
| Octagon Capital Advisors LP | 2,468,000 | $64,488,840 | 10.04% |
| NEA Management Company, LLC | 5,584,753 | $145,929,596 | 8.20% |
| Knoll Capital Management, LLC | 95,391 | $2,492,567 | 5.62% |
| Frazier Life Sciences Management, L.P. | 2,815,720 | $73,574,764 | 4.57% |
| Resolute Capital Asset Partners LLC | 185,992 | $4,860 | 4.34% |
| Caligan Partners LP | 183,064 | $4,783,462 | 3.98% |
| Samsara BioCapital, LLC | 695,001 | $18,160,376 | 3.91% |